165 related articles for article (PubMed ID: 9735921)
1. Hirudin versus heparin and low-molecular-weight heparin: and the winner is..
Hull RD; Pineo GF; Raskob GE
J Lab Clin Med; 1998 Sep; 132(3):171-4. PubMed ID: 9735921
[No Abstract] [Full Text] [Related]
2. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.
Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK
Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201
[TBL] [Abstract][Full Text] [Related]
4. Thrombin inhibitors in acute coronary artery disease.
Vorchheimer DA; Fuster V
Eur Heart J; 2002 Aug; 23(15):1142-4. PubMed ID: 12127916
[No Abstract] [Full Text] [Related]
5. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Krupinski K; Breddin HK
Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
[TBL] [Abstract][Full Text] [Related]
6. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
7. Is thrombin a pharmacological target during reperfusion?
White HD
Blood Coagul Fibrinolysis; 1999 Feb; 10 Suppl 1():S55-7. PubMed ID: 10070820
[No Abstract] [Full Text] [Related]
8. Future directions in antithrombotic therapy: emphasis on venous thromboembolism.
Axelrod DA; Wakefield TW
J Am Coll Surg; 2001 May; 192(5):641-51. PubMed ID: 11333101
[No Abstract] [Full Text] [Related]
9. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin.
Hansen JB; Naalsund T; Sandset PM; Svensson B
Thromb Res; 2000 Dec; 100(5):413-7. PubMed ID: 11150584
[No Abstract] [Full Text] [Related]
10. [Biochemical and pharmacological principles of antithrombotic therapy].
Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):293-312. PubMed ID: 63418
[No Abstract] [Full Text] [Related]
11. Anticoagulant and antithrombotic actions of recombinant hirudin.
Kaiser B
Semin Thromb Hemost; 1991 Apr; 17(2):130-6. PubMed ID: 1837615
[No Abstract] [Full Text] [Related]
12. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
Raake W; Klauser RJ; Elling H; Zeiller P
Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
[TBL] [Abstract][Full Text] [Related]
13. Recombinant hirudin is a heparin alternative in cardiac surgery.
Riess FC; Bleese N; Kormann J; Pötzsch B; Madlener K; Müller-Berghaus G; Greinacher A
J Cardiothorac Vasc Anesth; 1997 Jun; 11(4):538-9. PubMed ID: 9188012
[No Abstract] [Full Text] [Related]
14. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
15. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
16. [Heparin in surgery and artificial circulation: pro and contra. Is there an alternative?].
Roĭtman EV; Dement'eva II; Meshcheriakov AV
Anesteziol Reanimatol; 1997; (6):65-9. PubMed ID: 9511253
[No Abstract] [Full Text] [Related]
17. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
18. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
20. The effects of recombinant desulphatohirudin on arterial thrombosis in rats.
Talbot MD; Ambler J; Butler KD; Lees CM; Mitchell KA; Peters RF; Tweed MF; Wallis RB
Haemostasis; 1991; 21 Suppl 1():73-9. PubMed ID: 1654294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
